Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cel-Sci Corp (AMEX:CVM) (was HIV) -- Ignore unavailable to you. Want to Upgrade?

To: Tom Shutters who wrote (2195)	10/28/1998 11:19:00 AM
From: Michael DeLucia	Read Replies (1) \| Respond to of 2836

Epimmune Receives Grants From the NIH to Fund Hepatitis C and Aids Vaccine Research SAN DIEGO--(BW HealthWire)--Oct. 26, 1998--Epimmune Inc., a majority-owned subsidiary of Cytel Corporation (NASDAQ:CYTL), today announced that it has received two Phase II Small Business Innovation Research (SBIR) grants totaling $1.5 million from the National Institutes of Health (NIH) to investigate a new approach for treating and preventing viral infections. The NIH grant directed toward AIDS vaccine research is a two-year program entitled "Peptide-Based Vaccine for Primate Model of AIDS," to be conducted in collaboration with David I. Watkins, Ph.D., Associate Professor of the Wisconsin Regional Primate Research Center. Under the grant, the investigators will evaluate the ability of epitope-based genetic vaccines to elicit a cellular immune response in macaques monkeys targeted to multiple epitopes from simian immunodeficiency virus (SIV), an AIDS-like virus, and determine whether this response can protect against, or alter the course of, the viral infection. newsalert.com -------------------------------------------------------- Although this study appears to be competition for the company, we have already seen significant progress with Cel-Sci's Gag Peptide approach (HGP-30) by the way of NIH funded studies, major publications and Phase I / II ongoing studies. Plus they have two other drugs, Multikine and LEAPS, that may be combined with HGP-30 to produce a CURE for the virus. I believe the above article lends credibility to the approach and science of epitope-based vaccines and a change in thinking at NIH that approaches such as this may be our best chance at producing an effective AIDS vaccine / treatment. Good Luck, Mike D.